Antibe Therapeutics (“Antibe”) is a public biotech company with a drug platform of game-changing therapeutics in pain and inflammation. Its lead drug, ATB-346, recently showed unequivocal superiority to naproxen in GI safety, and its combined pipeline is targeting a global market opportunity in excess of $20 billion. Antibe’s commercial division in regenerative medicine is on a growth trajectory in the dental biologics market.
Pursuing Blockbuster Drug Opportunities in Pain & Inflammation
Antibe Therapeutics is pursuing a major advance in the safe and non-addictive treatment of pain and inflammation. Our drugs are designed to prevent the widespread and serious gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs (“NSAIDs”), today’s most widely used medicines for the relief of pain. The NSAID class of drugs includes prescription and over-the-counter (“OTC”) brands such as naproxen (Aleve), celecoxib (Celebrex), ibuprofen (Advil), and Aspirin.
Global NSAID sales exceed $11 billion annually, a significant market opportunity that could potentially be disrupted by Antibe’s H2S technology.
Regenerative Medicine Division Poised for Growth
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products for oral and maxillofacial surgery. Since its inception in 1997, Citagenix has become an important source of knowledge and experience in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. More recently, Citagenix initiated a strategic growth initiative in the United States, the largest global market for oral regenerative medicine.
Antibe’s subsidiary, Citagenix, is leveraging its market leading position in Canada to pursue a growth strategy in the dental biologics market.